ABL Bio, Inc.
Industry Group: Pharmaceuticals
Country/Region: South Korea
Identifier: KRX:298380
ABL Bio Inc is a Korean biotech research company. The company is engaged in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline products include ABL001 an Bispecific Antibody, ABL201-205 an Antibody Drug Conjugate, T cell engager, Dual Immune Cell Targeting BsAb an Immuno-Oncology, ABL301 an BBB-Penetrating Bispecific Antibody.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 748 out of 851
Universe
Global Universe 13343 out of 15104
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the non-India based rated subjects, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
China Shineway Pharmaceutical Group Ltd. |
29.5
Medium
|
415 out of 851 |
EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirim San ve Tic AS |
32.4
High
|
533 out of 851 |
Gen Ilaç ve Saglik Ürünleri Sanayi ve Ticaret AS |
36.6
High
|
731 out of 851 |
ABL Bio, Inc. |
37.1
High
|
748 out of 851 |
Voronoi, Inc. |
40
Severe
|
819 out of 851 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
ABL Bio, Inc.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
ABL Bio, Inc.'s Management of ESG Material Risk is Weak